Reviews Sirolimus


No reviews yet.

Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010





Other reviews about Sirolimus on wordpress

Secure Fixation After EVAR In Patients With Wide Aortic Necks: A Safe And Effective Alternative To Open Surgery In Many Patients, Trial Shows
  by healtherm2
Recanalization of infrapopliteal arteries is important in patients with chronic limb ischemia to decrease limb-loss. Dr. Konstantinos Katsanos, of the Department of Radiology, Patras University Hospital School […]


CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Now Approved In The European Union For Treatment Of Patients With Diabetes
  by enartion
The CYPHER SELECT®Plus Sirolimus-eluting Coronary Stent has received CE marking within the European Union (EU) for treatment of patients with diabetes, a complex and often difficult-to-treat patient population. […]


NEVO Sirolimus-Eluting Coronary Stent Yields Superior Results To Taxus(R) Liberte(R) Stent In Pivotal Clinical Trial
  by healtherm2
At six months, the NEVO™ Sirolimus-eluting Coronary Stent, incorporating RES Technology™, was superior to the Taxus Liberte Stent in reducing tissue growth within the stent that can potentially […]


Health Canada: Important Safety Information on CellCept [Mycophenolate Mofetil] and its Associated Risk for Pure Red Cell Aplasia (PRCA)
  by thassodotcom
June 6, 2009 - From a new posting on Health Canada’s website, we learn that on June 03, 2009, in consultation with Health Canada, Hoffmann-La Roche Limited (Roche), […]


FDA MedWatch - Sirolimus (marketed as Rapamune)
  by irbtipoftheweek
FDA notified healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after conversion from a calcineurin inhibitor (CNI)-based immunosuppressive regimen to sirolimus […]


Clinical Trial Data that Suggest Increased Mortality in Stable Liver Transplant Patients Receiving Sirolimus [Rapamune]
  by thassodotcom
June 11, 2009 - From a today’s  MedWatch Safety Alert we learn that the American Food and Drug Administration (FDA) notified healthcare professionals of clinical trial data that […]


DNA damage can trigger the development of (prostate) cancer, accelerate aging, or both
  by Jim Tucker
NEW ENGLAND JOURNAL OF MEDICINE: DNA damage can trigger the development of cancer, accelerate aging, or both, writes Dr Jan H.J. Hoeijmakers, Erasmus University Medical Center, Rotterdam. When the […]


Quiz: Uma massa colonica em um receptor de transplante renal
  by Edmilson Lima
Quiz Page January 2010: A Colonic Mass in a Kidney Transplant Recipient American Journal of Kidney Diseases Volume 55, Issue 1, Pages A35-A37 (January 2010) Clinical Presentation A 60-year-old woman was […]


FDA MedWatch - Rapamune (sirolimus): Drug Monitoring Recommendations
  by irbtipoftheweek
Wyeth notified healthcare professionals of changes to the Rapamune Prescribing Information regarding changes in the performance of an immunoassay used for therapeutic drug monitoring (TDM) of sirolimus. The […]


Toxicidade Tubular do Sirolimus
  by Edmilson Lima
Tubular Toxicity in Sirolimus- and Cyclosporine-Based Transplant Immunosuppression Strategies: An Ancillary Study From a Randomized Controlled Trial Stefan Franz, MD1, Axel Regeniter, MD2, Helmut Hopfer, MD3, Michael Mihatsch, MD3, Michael Dickenmann, MD American Journal of […]



Other reviews about Sirolimus on web:

Sirolimus (INN / USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. Sirolimus - Wikipedia, the free encyclopedia


Sirolimus Key Terms: Immune system , Immunosuppressant , Lymphocele , Lymphoma , Steroids . Definition Sirolimus is indicated by the Food and Drug Sirolimus: Information from Answers.com


Learn about the prescription medication Rapamune (Sirolimus), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Rapamune (Sirolimus) Drug Information: Uses, Side Effects, Drug ...


All about Sirolimus Tablets. View complete and up to date Sirolimus information - part of the Drugs.com trusted medication database. Sirolimus Tablets Facts and Comparisons at Drugs.com


Physician reviewed sirolimus patient information - includes sirolimus description, dosage and directions. sirolimus medical facts from Drugs.com


Sirolimus is a medicine with immunosuppressant and antifungal properties, used for the prevention of rejection in organ transplantation and for the symptomatic treatment of tuberous ... Sirolimus at Miami Children's Brain Institute


sirolimus /si·ro·li·mus/ (sĭ-ro´lĭ-mus) a macrolide antibiotic having immunosuppressant properties; used to prevent rejection of kidney transplants. sirolimus - definition of sirolimus in the Medical dictionary - by ...


Mayo Clinic offers award-winning medical and health information and tools for healthy living. Sirolimus (Oral Route) - MayoClinic.com


Learn more about Sirolimus. Find the Web's best health guides, medical reports, news, videos and tools for Sirolimus. Share Sirolimus experiences and get advice from experts. Sirolimus Overview - References, Advice, News, Videos, Coping ...


Sirolimus may increase the risk that you will develop an infection or cancer, especially lymphoma (cancer of a part of the immune system) or skin cancer. Sirolimus: MedlinePlus Drug Information





Featured Reviews

Reviews Halog Cream

Halog Cream Drug Description HALOG® (halcinonide) Cream, USP 0.1% For Topical Use Only. Not For Ophthalmic Use. DRUG DESCRIPTION What are the possible side effects of halcinonide topical (Halog, Halog-E)? Get emergency...
Read More  |  Review This
Reviews Rosuvastatin Calcium

Crestor Drug Description CRESTOR (rosuvastatin calcium) Tablets DRUG DESCRIPTION What are the possible side effects of rosuvastatin (Crestor)? Get emergency medical help if you have any of these signs of an allergic reaction: hives;...
Read More  |  Review This
Reviews Requip

Requip Drug Description REQUIP® (ropinirole hydrochloride) Tablets DRUG DESCRIPTION What are the possible side effects of ropinirole (Requip, Requip XL)? Get emergency medical help if you have any of these signs of an allergic...
Read More  |  Review This
Reviews Sodium Hyaluronate

Provisc Drug Description PROVISC® (1% Sodium Hyaluronate) Viscoelastic Preparation DRUG DESCRIPTION PROVISC® Viscoelastic Preparation is a sterile, non-pyrogenic, high molecular weight, noninflammatory highly purified...
Read More  |  Review This
Reviews Valganciclovir Hcl

Valcyte Drug Description Valcyte (valganciclovir hydrochloride) Tablets Valcyte (valganciclovir hydrochloride) for Oral Solution WARNING HEMATOLOGIC TOXICITY, CARCINOGENICITY, TERATOGENICITY, AND IMPAIRMENT OF FERTILITY Clinical...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....